Deletions of chromosomal region 9p21 are among the most common genetic alterations observed during the clonal evolution of high grade malignant gliomas. Structural and functional evidence has suggested that homozygous deletion involving CDKN2A (the genetic locus encoding the cyclin-dependent kinase inhibitor p16 INK4a ) is a mechanism of inactivation of this gene and that it can be a growth suppressor in human gliomas. However, the presence of other potential suppressor genes in the 9p21 region and the relatively large sizes of the deletions has made it dicult to be certain that the CDKN2A gene is their actual target. Here, we tested this hypothesis by determining the growth suppressive eects, cell cycle inhibitions, and the activities of seven naturally occurring glioma-derived CDKN2A alleles carrying point mutations and found that two of them were functionally compromised. To resolve discrepancies among the dierent existing functional assays, we developed an assay for p16
Introduction
Malignant tumors originate and progress through a multistep process in which growth-advantageous genetic events accumulate (Nowell, 1976) . This clonal evolution model has undergone rigorous evaluation during the progression of malignant gliomas, leading to the identi®cation of multiple speci®c genetic defects such as loss of heterozygosity (LOH) of chromosome 17p, mutation of the p53 gene, overexpression of the platelet derived growth factor-a (PDGFa), LOH of chromosomes 22q, 19q, 9p and 13q including the retinoblastoma (RB) gene, as well as ampli®cation and in-frame truncation of the epidermal growth factor receptor (EGFR) gene (for reviews see Furnari et al., 1995; Louis et al., 1994) .
Among these genetic lesions, hemi-and homozygous deletions involving chromosome region 9p21 are the most common structural abnormality observed in malignant gliomas (James et al., 1993; Olopade et al., 1992) . The common occurrence of deletions of this region has prompted several studies to determine the frequency of alteration of the CDKN2A (MTS1/ p16 INK4a ) gene (Kamb et al., 1994; Nobori et al., 1994; Serrano et al., 1993) in the genetic progression of glial tumors (Gianni and Finocchiaro, 1994; He et al., 1994 He et al., , 1995 Jen et al., 1994; Kyritsis et al., 1996; Li et al., 1995; Moulton et al., 1995; Nishikawa et al., 1995; Schmidt et al., 1994; Ueki et al., 1994; Walker et al., 1995) . The accumulated structural evidence implicates the CDKN2A gene as a target of 9p21 deletions in gliomas. However, the presence of other potential suppressor genes within the 9p21 region such as the interferon gene cluster, the p15 INK4b gene (MTS2/CDKN2B) (Hannon and Beach, 1994) and an alternative transcriptional reading frame of the CDKN2A gene (Duro et al., 1995; Mao et al., 1995; Stone et al., 1995; Quelle et al., 1996) ; in addition to the relatively large sizes of the deletions, has made it dicult to establish that CDKN2A is their actual target (Cairns et al., 1995; Jen et al., 1994) . First, the search for chromosome structural abnormalities has been hampered by technical diculties with PCR analysis of the CDKN2A region which has proven unreliable and dicult to quantitate due to contaminating normal tissue, poor ampli®cation of GC-rich sequences, and the need for multiple closely spaced polymorphic markers to detect small deletions (Cairns et al., 1995) . Second, structural analysis of 9p21 likely underestimates the importance of CDKN2A as a glioma suppressor gene since it does not address epigenetic mechanisms of p16
INK4a inactivation such as transcriptional silencing due to aberrant methylation (Costello et al., 1996; Merlo et al., 1995; Nishikawa et al., 1995) or modulation by other genes in the p16 INK4a pathway such as CDK4 ampli®cation and overexpression (He et al., 1994 (He et al., , 1995 Nishikawa et al., 1995; Schmidt et al., 1994 ). Third, a further level of complexity is created by examples of mutant CDKN2A alleles derived from familial cases of malignant melanomas and pancreatic carcinomas which do not seem to segregate with the tumors and appear to have only a minor impact on p16 INK4a function (Goldstein et al., 1995; Ranade et al., 1995) .
Although the predominant mode of inactivation of CDKN2A seems to be homozygous deletions, the sequence of the CDKN2A gene has been examined and a number of intragenic point mutations have also been found in primary malignant gliomas (Gianni and Finocchiaro, 1994; Jen et al., 1994; Kyritsis et al., 1995 Kyritsis et al., , 1996 Li et al., 1995; Moulton et al., 1995; Nishikawa et al., 1995; Schmidt et al., 1994; Ueki et al., 1994; Walker et al., 1995) . Their functional signi®cance, however, has not been elucidated. These include 13 alleles containing missense (A73T, A76V,  A85T, T93R, H98Y, A102V, V106M, R107C, P114L,  P114S, A127V, R128W , and G136D) and one allele containing nonsense (W110*) mutations. All are located in exon 2 of CDKN2A, where they are distributed in the second (A73T), between the second and third (A76V), third (A85T, T93R, H98Y, A102V, V106M and R107C) and fourth (W110*, P114L, P114S, A127V, R128W and G136D) ankyrin repeats of p16
INK4a
. The W110* mutation has also been observed in one melanoma cell line (Kamb et al., 1994) and two pancreatic adenocarcinoma xenografts (Caldas et al., 1994) while the P114L mutation was also reported in two melanoma cell lines (Kamb et al., 1994) .
It has been postulated that CDKN2A is the ®rst example of a tumor suppressor gene in which each allele is most frequently inactivated by two independent deletion events (Kamb, 1995; Liu et al., 1995) , consistent with a two-hit model (Knudson et al., 1975) and with the low incidence of point mutations observed in primary tumors (Cairns et al., 1995) . Moreover, we have previously demonstrated that replacement of a wild-type CDKN2A allele in CDKN2A null human glioma cells suppresses their growth (Arap et al., 1995) . This work provided evidence that the CDKN2A gene could function as a glioma growth suppressor, but the overexpression of this cell cycle regulator could have downstream eects, despite the care with which expression levels approximating those of the endogenous levels were maintained (Arap et al., 1995) . Following on these data, we reasoned that a demonstration that the rare naturally occurring intragenic point mutations caused loss of function would provide strong evidence that the CDKN2A gene is a critical target of the 9p21 deletions in malignant gliomas. Here, we tested this hypothesis by determining the growth suppressive eect, cell cycle inhibition, and the in vitro and in vivo activities of a series of seven naturally occurring glioma-derived CDKN2A alleles carrying point mutations and found that two of them were functionally impaired. We also developed a novel in vivo assay that allowed us to demonstrate that the expression of wildtype CDKN2A, but not alleles with inactivating mutations, exert their eects by preventing pRB phosphorylation in human glioma cells.
Results

Glioma-derived cells whose p16
INK4a
-RB pathways have been characterized were used as recipients for CDKN2A gene transfer. In order to test for loss-offunction eects, we introduced seven dierent gliomaderived CDKN2A alleles (A73T, H98Y, V106M, R107C, W110*, P114L and P114S) separately into each of three human glioma cell lines: U-87MG and U-251MG, which are both endogenously p16 
/RB
7 (Arap et al., 1995) . We then compared the eect of these alleles on cell growth to that observed when the cells were transfected either with empty vector sequence or with the full length wild-type CDKN2A cDNA. After completion of drug selection, the growth suppression was quanti®ed by comparing the number of drug resistant cells in cultures transfected with CDKN2A wild-type or mutant alleles to those of cultures transfected with empty vector (Figure 1 ). The growth suppressive eect of the A73T, H98Y, V106M, R107C, and P114S alleles was marked and not signi®cantly dierent from the eect of wild-type allele replacement (less than 30% of the relative cell number seen with empty control vector), while a relative relief of growth suppressive eect was observed with the W110* and P114L alleles (more than 70% of the relative cell number seen with empty control vector).
The expression of proteins from the various CDKN2A alleles was assessed in each case by Western blot analysis of p16
INK4a
; the data shown in Figure 2a are from analyses of U-251MG cells. No p16
INK4a was detectable in vector transfected U-251MG cells. The mutant CDKN2A transfectants showed p16
INK4a levels similar to those of other glioma cells which express endogenous wild-type CDKN2A alleles (Arap et al., 1995) . The exception was the nonsense mutation W110*, in which no protein was detected (Figure 2a ), although the levels of CDKN2A W110* mRNA were indistinguishable from those of CDKN2A wild-type mRNA by Northern blot analysis (Figure 2b ). Moreover, a band corresponding to the product of the W110* truncated p16
INK4a protein was detected in an in vitro transcription and translation assay (Figure 2c ) demonstrating the translatability of the mRNA derived from the pCDKN2W110* construct. Empty control vector and the construct pCDKN2WT were used as negative and positive controls, respectively, in this in vitro assay. Thus, since a translatable W110* transcript, but not its protein, can be detected in vivo, it is likely that this premature termination aects p16
INK4a protein stability. In order to determine if the growth suppressive eects of CDKN2A and lack of suppression by W110* and P114L were due to a speci®c block in the cell cycle, we transiently cotransfected the CD20 cell surface marker and the various CDKN2A alleles (Koh et al., Figure 1 Growth suppressive eect of CDKN2A allele replacement in human glioma cells. Ability of glioma-derived CDKN2A alleles to induce growth suppression in a stable transfection assay, following drug selection. The nomenclature indicates the location and identity of the amino acid changes. Viable cells were counted after G-418 selection. Results are normalized in terms of percentage of vector transfection with the vector control set to 100% in each case. A typical experiment is shown. These results were reproduced in three independent experiments CDKN2A mutations in glioma W Arap et al 1995; Lukas et al., 1995; van der Heuvel and Harlow, 1993) . Two days after the cotransfections, the cell cycle distribution of the population of CD20-positive cells was examined in each group. In both of the p16
INK4a negative glioma cell lines, the alleles A73T, H98Y, V106M, R107C and P114S induced a signi®cant increase in the G 1 population (to levels similar to those achieved by wild-type CDKN2A) and a reciprocal decrease in their G 2 and S populations. W110* and P114L elicited only a slight G 1 increase ( Figure 3 ). The cell cycle distribution of LN-319 cells, which contain endogenous wild-type CDKN2A alleles (Arap et al., 1995) and are pRB negative, was not signi®cantly altered by any of the constructs (Figure 3 ). Thus, these two alleles (W110* and P114L) appeared to encode severely compromised p16
INK4a proteins, while the ®ve others (A73T, H98Y, V106M, R107C and P114S) encoded proteins that were not signi®cantly dierent from the wild-type protein in their ability to induce G 1 arrest.
The capacity of the wild-type and mutant p16
proteins to prevent progression through the G 1 phase of the cell cycle generally correlates with their inhibition of CDK4 or CDK6 and D-cyclin activities (the only known targets of p16
) in vitro (Ranade et al., 1995; Lukas et al., 1995; Koh et al., 1995) . In order to test the eects of the glioma-derived mutations on these speci®c kinase activities, GSTp16 INK4a fusion proteins were tested for their ability to inhibit CDK4/cyclin D1 or CDK6/cyclin D1, using the retinoblastoma protein (pRB) as a substrate. . Western blot of wildtype and mutant p16
INK4a proteins in an endogenous CDKN2A null background (U-251MG) after stable transfections. The protein expression of wild-type and all mutant alleles, except W110*, was detected with an anti-p16
INK4a polyclonal antibody. Similar results were also observed in U-87MG cells transfected with CDKN2A constructs (data not shown). (b) Comparison of RNA expression of CDKN2A WT and W110* alleles. Upper panel. Northern blot analysis of CDKN2A wild-type and W110* transcripts in the glioma cells U-87MG and U-251MG, both with a CDKN2A null background. A 0.95 Kb band corresponding to the transfected CDKN2A alleles was detected using a p16
INK4a exon 1a speci®c probe as described (Arap et al., 1995) . In both cell lines, the levels of WT and W110* messages were expressed at comparable levels. Lower panel. Membrane staining of the 18S RNAs with methylene blue (Herrin and Schmidt, 1988) showing equal loading of total RNA. (c) In vitro transcription and translation of CDKN2A WT and W110* constructs. A coupled in vitro transcription and translation assay followed by immunoprecipitation with an anti human p16 INK4a polyclonal antibody was performed. Empty control vector and pCDKN2WT were used as negative and positive controls respectively. In the lane corresponding to the W110* construct, a band of corresponding to the predicted size of the p16 INK4a truncated product at position 110 (approximately 11.5 kD) was detected, demonstrating the translatability of the W110* RNA transcript Figure 3 Eect of CDKN2A alleles on cell cycle progression. Ability of glioma-derived CDKN2A alleles to induce cell cycle G 1 arrest in a transient transfection assay. CDKN2A wild-type, mutant, or vector alone were transfected by the calcium phosphate method in duplicate 100 mm dishes. Two days after transfection, the eect of CDKN2A alleles on cell cycle progression, in a cell population identi®ed by cotransfection of limiting amounts of the surface marker CD20 (pCMV-CD20 : pCDKN2A molar ratio 1 : 4), was plotted as a function of DG 1 %. DG 1 % represents the percent change in the proportion of cells in G 1 relative to the vector control sample, and is de®ned by the equation (Koh et al., 1995) Titration of the in vitro inhibitory activity for each control vector, wild type, and for each mutant construct was performed, using the CDK4/cyclin D1 kinase. Increasing amounts of each of the GSTp16 INK4a fusion proteins (ranging from 100 to 800 ng) were used and, under the conditions of this assay, none of the alleles were able to inhibit pRB phosphorylation when up to 800 ng of the each of INK4a proteins were used (negative data not shown). Thus, the lack of inhibitory ability of the mutant alleles is unlikely to be due to concentration dierences. When 1 mg of the fusion GST-p16 INK4a was used, the product of each of the alleles, except P114L but including W110*, was able to prevent pRB phosphorylation by CDK4/cyclin D1 kinase (Figure 4a, upper panel) or by CDK6/cyclin D1 kinase in vitro (Figure 4a, middle panel) . Thus, the in vitro activities of the constructs which behaved comparably to the wild-type allele in the transfection studies (A73T, H98Y, V106M, R107C and P114S) also had essentially the same inhibitory activity as wild-type in vitro. In contrast, a comparison of the inhibitory eect of GST-p16
INK4a wild-type and P114L proteins demonstrated that increasing the P114L product to more than three times the amount of wild-type still resulted in an inability to inhibit pRB phosphorylation in vitro (Figure 4b) . A positive control assay showed that none of the p16
INK4
proteins could inhibit pRB phosphorylation by the CDK2/cyclin A kinase (Figure 4a, lower panel) , while a negative control assay with an irrelevant extract expressing large T antigen showed no pRB phosphorylation (negative data not shown). Therefore, the only discrepancy between our in vivo and in vitro results was the mutation W110*, which behaved as a severely defective protein in both growth suppression and cell cycle assays, but which was still similar to wild-type in its ability to inhibit pRB phosphorylation in vitro.
In order to address this problem, we devised an assay for in vivo p16
INK4a inhibition of pRB phosphorylation in which glioma cells were transiently cotransfected with limiting amounts of pCMV-RB large pocket (LP, residues 379-928) and either control vector or each of the CDKN2A (wild-type and mutant) constructs. Cotransfected glioma cells were then used to test the eects of the various CDKN2A alleles on RB phosphorylation in vivo using immunoprecipitation, electrophoresis, and analysis of the exogenous pRB/LP by immunoblotting. The ppRB/LP to pRB/LP ratio (ppRB/LP : pRB/LP) revealed the relative eects of the cotransfection of each of the CDKN2A alleles on the phosphorylation of the transfected RB/LP product, setting the ppRB/LP : pRB/LP ratio in the contransfection of empty vector control to 100%. The eects of the CDKN2A alleles A73T, H98Y, V106M, R107C and P114S were comparable to those observed upon transfer 
GST-p16
INK4a fusion proteins encoded by each of the indicated alleles were assayed for their ability to inhibit CDK4/cyclin D1, CDK6/Cyclin D1, or CDK2/Cyclin A, using a recombinant GST-RB SspI-End (SE, residues 768 ± 928) as the substrate for the three CDK/cyclin kinases. Here, a total of 1 mg of GST-p16 INK4a was used. All experiments were repeated at least three times. In the experiments shown, samples were resolved by 4 ± 20% gradient SDS ± PAGE. Upper panel. CDK4/cyclin D1 phosphorylation of RB assay. All fusion proteins except GST-p16
INK4a
P114L are able to inhibit pRB/SE phosphorylation. Middle panel. CDK6/cyclin D1 phosphorylation of RB assay. All fusion proteins except INK4a P114L are able to inhibit pRB/ SE phosphorylation. Lower panel. CDK2/cyclin A phosphorylation of RB assay. None of the fusion INK4a constructs are able to inhibit pRB/SE phosphorylation. (b) Titration of the in vitro activity of the P114L allele. The fusion protein GSTp16 INK4a P114L which contains an inactivating (p16M) mutation is unable to inhibit pRB phosphorylation even if 3 mg of its product are used. -66kD Figure 5 In vivo inhibition of RB phosphorylation assay. U-251MG glioma cells were cotransfected with limiting amounts of pCMV-RB large pocket (LP, residues 379 ± 928) and either empty control vector, wild-type, or mutant CDKN2A alleles. Cells cotransfected with a molar ratio of 1 : 15 (pCMV-RB/ LP : pCDKN2A) were used test to test the CDKN2A constructs. pRB/LP was immunoprecipitated, resolved by 8.5% SDS ± PAGE, and detected by immunoblotting. Shown below are the relative ppRB/LP to pRB/LP ratios, setting the vector control to 100%. The prevention of phosphorylation of the cotransfected native RB/LP construct observed after introduction of the CDKN2A A73T, H98Y, V106M, R107C and P114S alleles, which contain p16W mutations, is similar to that observed upon transfer of the CDKN2A wild-type allele in the CDKN2A null U-251MG glioblastoma cells. In contrast, the introduction of either the W110* or the P114L allele is unable to prevent the phosphorylation of pRB/LP in vivo. Thus, phosphorylation of the cotransfected pRB/LP product was similar to that observed in cells transfected with the empty control vector. Likewise, the relative ratio of ppRB/LP to pRB/LP is less than 30% in the wild-type, A73T, H98Y, V106M, R107C and P114S alleles, whereas the ratios in the alleles containing the loss-of-function mutations W110* and P114L are similar to that in the empty vector lane CDKN2A mutations in glioma W Arap et al of the CDKN2A wild-type allele (ppRB/LP : pRB/ LP530%), while the introduction of either W110* or P114L allele was unable to prevent the phosphorylation of pRB/LP, and was comparable to the eect observed in glioma cells transfected with the control vector ( Figure  5 ). The results of this assay clearly demonstrate that W110* and P114L are loss-of-function alleles, containing p16 INK4a inactivating mutations.
Discussion
A modest, yet signi®cant number of single base alterations in CDKN2A have been detected in primary glial tumors. Until now, the relevance of these putative CDKN2A point mutations in the biology of human gliomas has remained largely unknown. Here, we present a functional analysis of a series of glioma-derived mutant CDKN2A alleles. A novel in vivo assay of inhibition of RB phosphorylation was also used in our study. Based on the ability to induce G 1 arrest or their long term growth suppression, the CDKN2A alleles which behaved similarly to wildtype were classi®ed as p16W alleles, whereas the glioma-derived CDKN2A alleles exhibiting impaired function were classi®ed as p16M alleles (Goldstein et al., 1995) . The p16W alleles (A73T, H98Y, V106M, R107C and P114S) aected either growth suppression or cell cycle distribution to levels greater than 70% of the wild-type CDKN2A allele, while the p16M alleles (W110* and P114L) aected each of the parameters by less than 30% relative to wild-type. Therefore, both transient and stable CDKN2A gene transfer into human glioma cells revealed consistent results. The ability of p16 INK4a proteins to prevent CDK4 or CDK6/cyclin D1 phosphorylation of pRB was measured in vitro ( Figure 4a ) and shown to be generally correlated with the transfection results, and our results for the comparative titration of the eects of p16
INK4a WT and P114L ( Figure 4b ) were also consistent with previously reported in vitro data (Koh et al., 1995; Lukas et al., 1995) . Thus, the exception was the W110* allele, in which a nonsense mutation is located in the ®rst residue of the fourth ankyrin repeat of the p16
INK4a protein, generating a truncated protein which behaved as a loss-of-function allele in transfection experiments but was able to inhibit pRB phosphorylation in vitro (Figure 4a ). Since the levels of WT and W110* RNA are similar by Northern blot analysis (Figure 2b) , these results could be explained either by an inability of the W110* RNA to be translated or by protein instability of a prematurely truncated protein. An in vitro transcription and translation assay demonstrated that the W110* RNA message is translatable. Taken together, one explanation for these observations is that while the native protein is unstable and undetectable in vivo (Figure 2a) , the INK4a W110* fusion construct is expressed and able to function in vitro (Figure 4a) , representing a limitation of the latter to model the former. These ®ndings are consistent with the previous suggestions that the COOH-terminal region of p16
INK4a may be involved in the stability of the protein (Yang et al., 1995) and that the majority of the CDKN2A premature terminations are inactivating mutations (Parry and Peters, 1996) . Other discrepancies between the ability of CDKN2A alleles to arrest cell cycle progression and their inhibition of CDK4/ cyclin D1 kinase activity by recombinant p16
INK4a in vitro have also been reported (Koh et al., 1995) emphasizing the need for a more reliable and accurate assay to assess the in vivo biochemical function of p16
INK4a
. We designed a novel in vivo assay of inhibition of pRB phosphorylation (Figure 5 ), which overcomes some of the limitations of the in vitro assays, such as the possibility of protein instability, and it has the advantage of simultaneously assessing both known (CDK4 or CDK6/cyclin D1 or D2 or D3) and unknown p16
INK4a driven pathways to RB phosphorylation. The results of this assay unequivocally con®rm that the alleles W110* and P114L indeed contain lossof-function mutations, in complete accordance with the results of our growth arrest and cell cycle assays (Figures 1 and 3) , suggesting that this in vivo assay provides a more reliable method to functionally evaluate mutations of the INK4 family (and, perhaps, mutations in other cyclin-dependent kinase inhibitors such as p21 WAF1 or p27 KIP ) than previously reported in vitro assays (Koh et al., 1995; Lukas et al., 1995; Parry and Peters, 1996; Ranade et al., 1995; Yang et al., 1995) .
Recently, a 20-residue peptide corresponding to amino acids 84 to 103 of the third ankyrin repeat of p16
INK4a was demonstrated to inhibit pRB phosphorylation in vitro (FaÊ hraeus et al., 1996) . Since the inactivating mutations W110* and P114L are located outside this functional domain, they are likely to disrupt it by distinct molecular mechanisms, such as protein instability and allosteric conformational changes, respectively. However, not only the codon location, but also the speci®c amino acid changes appear to be relevant for the function of the p16
INK4a protein. For instance, the H98Y and P114S alleles behave as wild-type (p16W) alleles, as opposed to H98P (Koh et al., 1995) and P114L (Koh et al., 1995; Lukas et al., 1995) , which are loss-of-function (p16M) alleles containing inactivating mutations.
As established above, two of seven CDKN2A sequence alterations signi®cantly diminish p16 INK4a function, leaving open the question of the remaining ®ve non-inactivating mutations. A prediction of our functional analysis is that the p16W alleles, which appear to contain non-inactivating mutations, would confer no selective growth advantage in relation to the wild-type p16 INK4a allele (Sidransky et al., 1992) . Indeed, these ®ve alleles (A73T, H98Y, V106M, R107C, P114S) were reported in malignant gliomas (Kyritsis et al., 1995 (Kyritsis et al., , 1996 but each of these CDKN2A mutations was detected only in a small percentage of the tumor cells by individual colony sequencing and Southern hybridization, consistent with heterogeneous glioma cell populations (Kyritsis et al., 1996) , in which the mutations do not appear to have been selected. While the biological signi®cance of these p16W mutations remains uncertain, this phenomenon was observed in other tumors such as malignant melanomas and pancreatic carcinomas (Goldstein et al., 1995; Ranade et al., 1995) . One explanation may lie with p16b, a novel human p16
INK4a transcript (Duro et al., 1995; Mao et al., 1995; Stone et al., 1995) or an unrelated protein from an alternative reading frame of the murine p16
INK4a gene (p19 ARF ) which has recently been reported and shown to be capable of inducing G 1 and also G 2 phase arrest independent of CDK4 or CDK6 (Quelle et al., 1995) . Most of the p16 INK4a glioma-derived mutations studied here (A73T, H98Y, V106M, R107C, W110*, P114L, P114S) would be expected to alter dierent codons in the human p16b reading frame (respectively R87H, A112V, R120H, A121V, G125R, A128A, A128V). The P114L allele, which demonstrably contains a p16
INK4a loss-of-function mutation, would correspond to a silent mutation in the p16b reading frame. Thus, we are currently exploring the possibility that some of the so-called p16W alleles may actually represent p16b inactivating mutations.
These considerations caution that the ®nding of a CDKN2A sequence alteration may not always indicate a defective p16 INK4a protein. Without exhaustive functional assessment, the possibilities of p16W alleles, polymorphisms, additional reading frames, or even sequencing errors due to the very high GC-rich nature of the CDKN2A gene still exist. Nonetheless, the data reported here show that the CDKN2A gene can be a speci®c target for mutational inactivation in human glial tumors.
Materials and methods
CDKN2A plasmid construction and protein puri®cation
The mammalian expression construct pCDKN2WT has been previously described (Arap et al., 1995) and used for construction of the mutant CDKN2A alleles. Site-directed mutagenesis by recombinant PCR with Pfu polymerase (Stratagene, La Jolla) was used to construct the CDKN2A alleles containing the point mutations (Arap et al., 1995) . All constructs were cesium chloride puri®ed twice before use in transfection experiments. Wild-type and mutant CDKN2A alleles were sequenced using the dideoxy method (USB, Cleveland, OH).
The wild-type and mutant CDKN2A cDNAs were fused in-frame to the GST gene in the vector pGEX-5X-3 (Pharmacia, Piscataway, NJ). The expression of each of the GST fusion proteins was induced with 1 mM IPTG (Stratagene, La Jolla, CA) and allowed to proceed for 6 h at 308C. GST-p16
INK4a
and GST-pRB fusion protein puri®cation was accomplished by gluthatione anity column chromatography according to the manufacturer's instruction (Pharmacia, Piscataway, NJ).
CDKN2A transfection and growth suppression assay
The human glioma cell lines selected for use in this study have been previously described (Arap et al., 1995) . U-87MG and U-251MG were derived from glioblastomas and LN-319 from an anaplastic astrocytoma.
Transfections were performed by the calcium phosphate method as previously described (Arap et al., 1995) , using 20 mg of either empty vector (pcDNA3) or pCDKN2A alleles (wild-type or each of the mutant constructs) per 100 mm dish. Transfections were terminated after 12 h and 48 h post-transfection, cells were either split at a 1 : 5 dilution and maintained for 7 ± 10 days in G418-containing (Geneticin, Gibco/BRL, Gaitherburg, MD) media to generate stable transfectants or analysed by¯ow cytometry. Trypan blue excluding cells were counted using a hemocytometer.
Analysis of CDKN2A RNA and p16
INK4a protein expression in vitro and in vivo CDKN2A Northern blots Total RNA was prepared from G418-resistant glioma cells and the CDKN2A RNA expression in the transfectants was analysed by Northern blots essentially as described (Arap et al., 1995) .
p16
INK4a Western blots After completion of drug selection, CDKN2A-transfected glioma cell lysates (20 ml from a vol/ vol sample buer/cell pellet solution) were boiled, resolved by a gradient 4 ± 20% SDS ± PAGE and transferred to Immobilon-P membranes (Millipore, Bedford, MA) as described (Arap et al., 1995; Nishikawa et al., 1995) . Sample loading was monitored by Ponceau S staining (Sigma, St Louis, MO). After blocking the non-speci®c sites, membranes were probed with anti-p16
INK4a polyclonal antibody (Pharmingen, San Diego, CA). Normal rabbit and mouse sera were used as negative controls. Bound antibody was detected by enhanced chemiluminescence according to the manufacturer's protocol (ECL, Amersham Corp, Arlington Heights, IL).
In vitro transcription and translation assays An in vitro transcription and translation assay of empty control vector, pCDKN2WT and pCDKN2W110* constructs was performed using the TNT-coupled system (Promega, Madison, WI). The products were immunoprecipitated in vitro using an antip16
INK4a polyclonal antibody (Pharmingen, San Diego, CA), resolved by a 16% SDS ± PAGE and detected by¯uorography.
Flow cytometric analysis of the cell cycle
Cell cycle analysis was performed using the CD20 system with minor modi®cations (Koh et al., 1995; Lukas et al., 1995; van der Heuvel and Harlow, 1993) . Brie¯y, quantification of cell cycle alterations was accomplished by cotransfection of pCMV-CD20, with either vector alone or each of the CDKN2A constructs. CD20 was cotransfected at a molar ratio of 1 : 4 (pCMV-CD20 : pCDKN2A) relative to test constructs. Forty-eight hours after transfection, cells were harvested, immunostained for CD20 antigen using a FITCconjugated anti-CD20 monoclonal antibody (Becton-Dickinson, San Jose, CA), ®xed with 0.25% paraformaldehyde (Sigma, St Louis MO) in PBS, and permeabilized with 0.03% saponin in PBS (Sigma, St Louis MO). Propidium iodide DNA staining was then used to determine cell cycle distribution of at least 5000 CD20-positive cells as described (Koh et al., 1995; Lukas et al., 1995) .
In vitro inhibition of RB phosphorylation assay Sf9 insect cell lysates containing CDK4/cyclin D1 or CDK6/cyclin D1 were prepared and kinase assays performed as described (Ranade et al., 1995) . For each reaction, 2 ml of baculoviral lysate was mixed with increasing amounts of GST-p16 INK4a fusion protein (100 ng to 1000 ng) in a total volume of 30 ml of kinase buer (20 mM Tris pH 8.0, 10 mM MgCl 2 , 1 mM EGTA) for 30 min at 308C. Following this pre-incubation, the kinase reactions were started by adding 500 ng of the bacterially expressed GST-Rb-SspI/End (SE, residues 768 ± 928) retinoblastoma protein (Welch et al., 1993) as a substrate and 10 mCi of [g-32 P]ATP (3000 Ci/mMol; Amersham), with the mixtures were then incubated for 30 min at 308C. Subsequent processing was done essentially as described (Ranade et al., 1995) .
In vivo inhibition of RB phosphorylation assay
Cotransfection of pRB/large pocket (LP, residues 379 ± 928) (Qin et al., 1992) with vector alone or CDKN2A constructs in the CDKN2A-null U-251 glioblastoma cells was performed as described above, at a molar ratio of 1 : 15 (pRB/LP : pCDKN2A). Forty-eight hours after transfection, cells were harvested and lysed in NET-N supplemented with protease and phosphatase inhibitors as previously described (Welch et al., 1993) . Lysates were clari®ed by centrifugation and subjected to immunoprecipitation with XZ91 monoclonal antibody (Pharmingen, San Diego, CA) and protein G-sepharose chromatography (Pharmacia, Piscataway, NJ). Immunoprecipitates were washed four times with NET-N, the proteins were solubilized by boiling in SDS sample buer and resolved by 8.5% SDS±PAGE. The samples were transferrd to Immobilon-P (Millipore, Bedford, MA) and pRB was detected using the anti-RB polyclonal antibody 851 as described (Welch et al., 1993) . The ratio of ppRB/LP to pRB/LP was determined using an a-Innotech IS-1000 analytical digitizer (Innotech, San Diego, CA) and the relative ratios for the dierent CDKN2A alleles were obtained by setting the control vector group at 100%.
